cancer of unknown primary

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

The Ontario Institute of Cancer Research-hosted Cancer Genome Collaboratory has amassed 650 TB of data and supported early discovery of mutations.

The companies will combine Empire's NGS services and FISH probe portfolio with Kromatid's Pinpoint probes and directional genomic hybridization technology.

Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.

The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.

Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Pages

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.